John C. McCormick
Mr.McCormick's primary responsibilities are in private equity investing and as a senior member of the HealthpointCapital research and investment team. He previously served as a member of the Board of Directors of Scient’x Groupe, SAS and currently serves on the Board of OrthoAccel Technologies, Inc. Mr. McCormick previously was a Principal at BPI Capital Partners, LLC where he worked closely with Tim Berkowitz, currently President of HealthpointCapital. In the 1990s, he was an Associate with Baker Nye, LP, a $600 million private investment fund. He started his career as a macroeconomic and financial analyst at the World Bank in Washington, DC.
Mr. McCormick is a member of the Leadership Board of the McGovern Institute of Brain Research at M.I.T. and on the Executive Committee of the Board of Associates of the Whitehead Institute, also at M.I.T. Mr.McCormick received a BSc. with honors from London School of Economics and an M.B.A. from the M.I.T. Sloan School of Management.
Recent Articles by John McCormick
TranS1 to buy Baxano MAR 4, 2013
This morning spinal implant maker TranS1 announced that it was merging with stenosis technology company Baxano. The deal, valued at a total of $23.6 million, is paid for primarily by TranS1 issuing new stock, although TranS1 will pay $500k of... more
HealthpointCapital's 2012 Sports Medicine Book of the Year: An Interview with the Author, Dr. Jordan Metzl JAN 8, 2013
As day-to-day practitioners in the orthopedic industry, you can well imagine we are reading copiously on the topic. Reflecting on what we pored through last year, we recommend this gem of a book on sports medicine by the Hospital for... more
Medtech Tax - Little Has Changed DEC 6, 2012
The Internal Revenue Service has recently posted final regulations on the medical device excise tax that was crafted to help offset the cost of Obamacare. As background, the federal government enacted into law a 2.3% tax on U.S. medical device... more
Gel-One HA Injection Found Not to Infringe AUG 7, 2012
Last week, Hyaluronic acid (HA) manufacturer Seikagaku and its distribution partner Zimmer were determined by a U.S. federal jury not to infringe on Genzyme's Synvisc-One HA injection. more
Globus Latest IPO Update a Positive for Industry JUL 27, 2012
This week, Globus Medical, which is well on its way to going public, made a key amendment to its IPO filing materials that indicate a positive for the challenged spine industry. The amendment also indicates that their IPO is imminent. more